Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNa Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of asthma, dermatomyositis, and all food allergies; and kinoid vaccine that simultaneously targets IL-4 and IL-13 allergies. The company was founded in 1993 and is based in Suresnes, France.
Frequently asked questions
What sector does Neovacs S.A. (ALNEV) operate in?
Neovacs S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Neovacs S.A. (ALNEV) current stock price?
As of the latest data, Neovacs S.A. stock price is €0.75, with a previous close of €0.75.
What is Neovacs S.A. (ALNEV) current market capitalization?
Neovacs S.A. market cap is approximately 35.25.
What is Neovacs S.A. (ALNEV) Earnings Per Share (EPS)?
The trailing EPS is -€221.36.
Does Neovacs S.A. (ALNEV) pay dividends?
No. Neovacs S.A. does not pay a dividend.
What is Neovacs S.A. (ALNEV) beta (volatility) score?
Neovacs S.A. has a beta of -1228.168, indicating lower volatility than the overall market.
